Literature DB >> 25363763

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Yu-Hwa Huang1, Chen Zhu2, Yasuyuki Kondo1, Ana C Anderson2, Amit Gandhi1, Andrew Russell3, Stephanie K Dougan4, Britt-Sabina Petersen5, Espen Melum6, Thomas Pertel2, Kiera L Clayton7, Monika Raab8, Qiang Chen9, Nicole Beauchemin10, Paul J Yazaki11, Michal Pyzik1, Mario A Ostrowski12, Jonathan N Glickman13, Christopher E Rudd8, Hidde L Ploegh4, Andre Franke5, Gregory A Petsko3, Vijay K Kuchroo2, Richard S Blumberg1.   

Abstract

T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25363763      PMCID: PMC4297519          DOI: 10.1038/nature13848

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

1.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

2.  Multiple sequence alignment using ClustalW and ClustalX.

Authors:  Julie D Thompson; Toby J Gibson; Des G Higgins
Journal:  Curr Protoc Bioinformatics       Date:  2002-08

3.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.

Authors:  Chen Zhu; Ana C Anderson; Anna Schubart; Huabao Xiong; Jaime Imitola; Samia J Khoury; Xin Xiao Zheng; Terry B Strom; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2005-11-13       Impact factor: 25.606

4.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

5.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function.

Authors:  Lauren W Collison; Creg J Workman; Timothy T Kuo; Kelli Boyd; Yao Wang; Kate M Vignali; Richard Cross; David Sehy; Richard S Blumberg; Dario A A Vignali
Journal:  Nature       Date:  2007-11-22       Impact factor: 49.962

6.  Tracking epitope-specific T cells.

Authors:  James J Moon; H Hamlet Chu; Jason Hataye; Antonio J Pagán; Marion Pepper; James B McLachlan; Traci Zell; Marc K Jenkins
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

7.  An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression.

Authors:  Clemens Neufert; Christoph Becker; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

8.  TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines.

Authors:  William D Hastings; David E Anderson; Nasim Kassam; Ken Koguchi; Edward A Greenfield; Sally C Kent; Xin Xiao Zheng; Terry B Strom; David A Hafler; Vijay K Kuchroo
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

9.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

Authors:  R Brad Jones; Lishomwa C Ndhlovu; Jason D Barbour; Prameet M Sheth; Aashish R Jha; Brian R Long; Jessica C Wong; Malathy Satkunarajah; Marc Schweneker; Joan M Chapman; Gabor Gyenes; Bahareh Vali; Martin D Hyrcza; Feng Yun Yue; Colin Kovacs; Aref Sassi; Mona Loutfy; Roberta Halpenny; Desmond Persad; Gerald Spotts; Frederick M Hecht; Tae-Wook Chun; Joseph M McCune; Rupert Kaul; James M Rini; Douglas F Nixon; Mario A Ostrowski
Journal:  J Exp Med       Date:  2008-11-10       Impact factor: 14.307

10.  The RosettaDock server for local protein-protein docking.

Authors:  Sergey Lyskov; Jeffrey J Gray
Journal:  Nucleic Acids Res       Date:  2008-04-28       Impact factor: 16.971

View more
  223 in total

1.  CEACAM1 regulates CD8+ T cell immunity and protects from severe pathology during Citrobacter rodentium induced colitis.

Authors:  Julia Zöller; Jana-Fabienne Ebel; Vishal Khairnar; Verena Schmitt; Robert Klopfleisch; Jana Meiners; Virginia Seiffart; Wiebke Hansen; Jan Buer; Bernhard B Singer; Karl S Lang; Astrid M Westendorf
Journal:  Gut Microbes       Date:  2020-06-10

Review 2.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

3.  Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice.

Authors:  Xianhong Du; Zhuanchang Wu; Yong Xu; Yuan Liu; Wen Liu; Tixiao Wang; Chunyang Li; Cuijuan Zhang; Fan Yi; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Cell Mol Immunol       Date:  2018-05-07       Impact factor: 11.530

4.  Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Authors:  Hyun-Bae Jie; Raghvendra M Srivastava; Athanassios Argiris; Julie E Bauman; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2017-04-13       Impact factor: 11.151

5.  Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Authors:  Ila Datar; Miguel F Sanmamed; Jun Wang; Brian S Henick; Jungmin Choi; Ti Badri; Weilai Dong; Nikita Mani; Maria Toki; Luis D Mejías; Maria D Lozano; Jose Luis Perez-Gracia; Vamsidhar Velcheti; Matthew D Hellmann; Justin F Gainor; Kristen McEachern; David Jenkins; Konstantinos Syrigos; Katerina Politi; Scott Gettinger; David L Rimm; Roy S Herbst; Ignacio Melero; Lieping Chen; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2019-05-03       Impact factor: 12.531

Review 6.  The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis.

Authors:  Uwe Rueckschloss; Stefanie Kuerten; Süleyman Ergün
Journal:  Histochem Cell Biol       Date:  2016-09-30       Impact factor: 4.304

7.  Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis.

Authors:  Xingwei Jiang; Tingting Zhou; Yan Xiao; Jiahui Yu; Shuaijie Dou; Guojiang Chen; Renxi Wang; He Xiao; Chunmei Hou; Wei Wang; Qingzhu Shi; Jiannan Feng; Yuanfang Ma; Beifen Shen; Yan Li; Gencheng Han
Journal:  Oncoimmunology       Date:  2016-08-03       Impact factor: 8.110

Review 8.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.